These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10931169)

  • 21. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
    Tosti S; Caruso R; D'Adamo F; Picardi A; Ali Ege M; Girelli G; Mauro FR; Maurillo L; Amadori S
    Ann Hematol; 1992 Nov; 65(5):238-9. PubMed ID: 1457584
    [No Abstract]   [Full Text] [Related]  

  • 22. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
    Weiss RB; Freiman J; Kweder SL; Diehl LF; Byrd JC
    J Clin Oncol; 1998 May; 16(5):1885-9. PubMed ID: 9586905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.
    Helman DL; Byrd JC; Ales NC; Shorr AF
    Chest; 2002 Sep; 122(3):785-90. PubMed ID: 12226014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia.
    Davidovitz Y; Ballin A; Meytes D
    Acta Haematol; 1997; 98(1):44-6. PubMed ID: 9210914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evan's syndrome precipitated by fludarabine therapy in a case of CLL.
    Sen K; Kalaycio M
    Am J Hematol; 1999 Jul; 61(3):219. PubMed ID: 10398320
    [No Abstract]   [Full Text] [Related]  

  • 26. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
    Nishida H; Murase T; Ueno H; Park JW; Yano T; Ikeda Y
    Leuk Res; 2006 Dec; 30(12):1589-90. PubMed ID: 16542723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
    Hocepied AM; Falkson CI; Falkson G
    S Afr Med J; 1996 May; 86(5):549-50. PubMed ID: 8711555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fludarabine and fatal hemolytic anemia].
    López L; del Villar V; Pascual T
    Sangre (Barc); 1995 Aug; 40(4):335-6. PubMed ID: 7482124
    [No Abstract]   [Full Text] [Related]  

  • 29. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
    Di Raimondo F; Giustolisi R; Cacciola E; O'Brien S; Kantarjian H; Robertson LB; Keating MJ
    Leuk Lymphoma; 1993 Sep; 11(1-2):63-8. PubMed ID: 8220155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia.
    Ford CD; Asch J; Pulsipher M; Petersen FB
    Br J Haematol; 2004 Aug; 126(4):623-4. PubMed ID: 15287959
    [No Abstract]   [Full Text] [Related]  

  • 31. Fludarabine in the treatment of lymphoproliferative malignancies.
    Feldman EJ; Keating MJ
    Cancer Invest; 1993; 11(3):314-8. PubMed ID: 8485654
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
    Gonzalez H; Leblond V; Azar N; Sutton L; Gabarre J; Binet JL; Vernant JP; Dighiero G
    Hematol Cell Ther; 1998 Jun; 40(3):113-8. PubMed ID: 9698219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia.
    Bay JO; Fouassier M; Béal D; Alcaraz L; Cure H; Chollet P; Plagne R; Travade P
    Hematol Cell Ther; 1997 Aug; 39(4):209-12. PubMed ID: 9352330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
    Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
    Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
    Obeid KM; Aguilar J; Szpunar S; Sharma M; del Busto R; Al-Katib A; Johnson LB
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):66-9. PubMed ID: 22000698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Whipple's disease as a complication of chronic lymphocytic leukemia treated with fludarabine].
    Kuliszkiewicz-Janus M; Małecki R; Kuliczkowski K; Jeleń M
    Pol Arch Med Wewn; 2002 Sep; 108(3):887-91. PubMed ID: 12600186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progressive multifocal leukoencephalopathy in a patient with chronic lymphatic leukemia treated with fludarabine].
    Mata MI; Gardella S; del Mar Castellanos M; Ortiz MR
    Med Clin (Barc); 2000 Nov; 115(15):598-9. PubMed ID: 11141397
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
    Summerfield GP; Taylor PR; Mounter PJ; Proctor SJ
    Br J Haematol; 2002 Mar; 116(4):781-6. PubMed ID: 11886381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
    Maclean R; Meiklejohn D; Soutar R
    Br J Haematol; 1996 Mar; 92(3):768-9. PubMed ID: 8616054
    [No Abstract]   [Full Text] [Related]  

  • 40. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
    Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
    Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.